Breast Cancer Survivors at Increased Risk for Ovarian Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

SAN FRANCISCO-Women who have survived breast cancer are at increased risk for subsequent ovarian cancer, and this risk is especially high in women diagnosed with breast cancer before age 50 and in African-American, Asian, and Hispanic women, according to data presented at the 30th Annual Meeting of the Society of Gynecologic Oncologists.

SAN FRANCISCO—Women who have survived breast cancer are at increased risk for subsequent ovarian cancer, and this risk is especially high in women diagnosed with breast cancer before age 50 and in African-American, Asian, and Hispanic women, according to data presented at the 30th Annual Meeting of the Society of Gynecologic Oncologists.

Minorities Have Higher Rates

Wendy R. Brewster, MD, and her colleagues from the University of California, Irvine, found relative risks (RRs) for ovarian cancer in women diagnosed with breast cancer before age 50 of 1.79 for non-Hispanic white women, 2.38 for African-American women, 2.86 for Asian women, and 3.95 for Hispanic women.

“We often think of breast cancer as a disease of Caucasian women,” Dr. Brewster said in an interview. “When you see such high rates of subsequent ovarian cancer in Asian and Hispanic women, it raises the question of a possible genetic susceptibility.” She pointed out that there has been little work on genetic susceptibility in African-American, Asian, or Hispanic women.

The analysis, based on data from the Surveillance, Epidemiology and End Results (SEER) database, included 120,380 women with breast cancer. Patients were stratified by age at diagnosis of breast cancer, stage of breast cancer and race/ethnicity. Ovarian cancer as a subsequent primary malignancy was diagnosed in 478 of these women. The overall relative risk of ovarian cancer after a diagnosis of breast cancer was 1.30.

Risk was significantly elevated in women diagnosed with breast cancer before age 50 (RR 1.93). The largest increased risk of ovarian cancer was in women diagnosed with breast cancer between the ages of 15 and 39 (RR 3.21).

Women age 50 or less at diagnosis of stage I/II breast cancer had a higher relative risk of ovarian cancer than those diagnosed with more advanced breast cancer at the same age (2.24 vs 1.52, P < .05). Stage did not influence risk in postmenopausal women.

The most immediate implication of her research pertains to how patients are counseled. “Patients do not so commonly die from breast cancer now,” she said. “We find it in earlier stages. Ovarian cancer is a much more lethal disease, and a higher percentage of women with ovarian cancer die, partly because it is not detected early. We still do not have a good screening tool for ovarian cancer.”

The main options for high-risk women are triple screening for those who want to retain childbearing ability, or removal of the ovaries. “If you are younger, a lethal disease portends a much shortened life, compared with developing the same disease decades later,” Dr. Brewster noted.

Ovariectomy or more intensive screening should be considered, she said, and this may require a shift in the patient’s health emphasis.

“Those diagnosed with breast cancer may be less concerned about having regular pelvic examinations because so much of their attention has been directed to the breast cancer,” Dr. Brewster said. “The patient diagnosed with breast cancer before the age of 50 and the black, Hispanic, or Asian patient with breast cancer should be counseled to have careful, regular screening due to the increased risk of ovarian cancer.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content